Lactococcus lactis subsp.lactis inm3113 with cholesterol lowering function and application of lactococcus lactis subsp.lactis inm3113

By screening and identifying the subspecies of Lactococcus lactic acid inm3113, the side effects and insufficient resources caused by drugs in the prior art were solved, and the cholesterol and lipoprotein levels were significantly reduced in mice, and the cholesterol and lipoprotein levels were demonstrated. Potential in preparing cholesterol-lowering and probiotic products.

CN118909865APending Publication Date: 2024-11-08ZHEJIANG INM FOOD CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411126082.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has side effects caused by long-term medication use in reducing hypercholesterolemia, and there are few probiotic products in China that have cholesterol-lowering effects, resulting in insufficient resource exploration.

Method used

A subspecies of Lactococcus lactic acid inm3113 was screened and identified. This strain had a cholesterol degradation rate of 30.03%, and delayed weight gain and regulated serum lipoprotein levels in mouse experiments, while also having an inhibitory effect on certain pathogenic bacteria. , suitable for the preparation of cholesterol-lowering and probiotic products.

Benefits of technology

Lactococcus lactic acid subspecies inm3113 significantly reduces the cholesterol and lipoprotein levels in mice, has good safety and antibiotic sensitivity, has industrial value, and provides a safe and effective cholesterol-lowering strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909865A_ABST
    Figure CN118909865A_ABST
Patent Text Reader

Abstract

The invention provides a Lactococcus lactis subsp. Lactis inm3113 with a cholesterol lowering function and application of the Lactococcus lactis subsp. Lactis inm3113, the Lactococcus lactis subsp. Lactis inm3113 is preserved in Guangdong Microbial Culture Collection Center on July 17, 2024, the preservation number is GDMCCNO: 64880, and the preservation number is CGMCC NO: 64880. The Lactococcus lactis subsp. Lactis inm3113 has the advantages that the Lactococcus lactis subsp. Lactis inm3113 is preserved in the Guangdong Microbial Culture Collection Center on July 17, 2024; the preservation address is the fifth floor of the building 59, No.100 courtyard, Xianlie Middle Road, Guangzhou City. The lactococcus lactis subsp.lactis has the advantage of lowering cholesterol.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a strain of Lactococcus lactis subspecies lactis inm3113 with cholesterol-lowering function and application thereof. Background Art

[0002] Cholesterol is a type of cyclopentane polyhydrophenanthrene derivative that can be synthesized by the human body and is an indispensable substance for normal life activities. However, the unhealthy lifestyle of many people nowadays causes their cholesterol levels to be too high, resulting in hypercholesterolemia, which will undoubtedly increase the risk of cardiovascular disease. At present, oral statins, fibrates and other drugs are mainly used to reduce the cholesterol content in patients with hypercholesterolemia, but long-term medication may cause varying degrees of damage to the human body (the improvement effect and mechanism of Chuju total flavonoids on hypercholesterolemia), including reduced digestive ability, impaired liver function, rhabdomyolysis, etc. Therefore, it is necessary to find a new cholesterol-lowering strategy. Probiotics are a type of microorganism that is considered safe and beneficial to the human body. It is reported to have the potential to regulate sugar and lipid metabolism, improve memory, maintain digestive tract health, enhance immunity, and improve mood. In recent years, it has become a hot topic in industry-university-research. In terms of lowering cholesterol, many studies have also revealed the potential of probiotics: Nakamura et al. found that Lactobacillus amyloliquefaciens CP1563 significantly reduced the levels of triglycerides, total cholesterol, and low-density lipoprotein in obese people, and reduced their body fat rate and visceral fat; LEE et al. found that Bifidobacterium longum SPM1207 could significantly reduce the levels of total cholesterol and low-density lipoprotein in the serum of high-fat mice and reduce body weight and intestinal harmful enzyme activity; YANG et al. found that Lactobacillus buchneri could reduce the weight of mice and reduce the levels of triglycerides and cholesterol in serum; in addition, Lactobacillus plantarum and Lactobacillus casei were also reported to have similar cholesterol-lowering effects. However, there are relatively few probiotic products with cholesterol-lowering effects that have been industrialized in my country, which is mainly due to the lack of breadth and depth of probiotic resource mining. Therefore, it is necessary to carry out screening research on cholesterol-lowering lactic acid bacteria. Summary of the invention

[0003] In view of the above problems, the present invention provides a strain of Lactococcus lactis subspecies inm3113 having cholesterol-lowering function and application thereof.

[0004] The purpose of the invention is achieved through the following scheme: A strain of Lactococcus lactis subsp. lactis inm3113 with cholesterol-lowering function, Lactococcus lactis subsp. lactis (Lactococcus lactis subsp. lactis) inm3113, was deposited in Guangdong Provincial Microbiological Culture Collection Center on July 17, 2024, with the deposit number: GDMCCNO: 64880; the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0005] Furthermore, it has a 16S rDNA sequence as shown in SEQ ID NO:1.

[0006] The invention discloses an application of Lactococcus lactis subspecies lactis with cholesterol-lowering function in the preparation of cholesterol-lowering products.

[0007] The invention discloses an application of Lactococcus lactis subspecies lactis with cholesterol-lowering function in the preparation of probiotic products.

[0008] Furthermore, probiotic products include functional dairy products, functional beverages, fermentation agents, bacterial powders and bacteriocins.

[0009] The invention has the following advantages: the degradation rate of cholesterol by lactococcus lactis subspecies inm3113 reaches 30.03%. In a mouse test, the weight increase rate of mice fed with a high-fat diet can be delayed and the concentrations of serum cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein can be adjusted. In an antibacterial experiment, the metabolites of the strain have a certain inhibitory effect on Staphylococcus aureus CMCC26003, Listeria monocytogenes CMCC54007, Escherichia coli O157:H7 ATCC25922 and Salmonella typhimurium ATCC13311, and show good sensitivity to four common antibiotics (ampicillin, cefazolin, gentamicin and tetracycline). Therefore, the lactococcus lactis subspecies inm3113 has good cholesterol-lowering ability and probiotic characteristics, good safety and certain industrial value. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 This is the colony morphology of Lactococcus lactis subsp. lactis.

[0011] Figure 2 This is a picture of Lactococcus lactis subsp. lactis observed under a microscope.

[0012] Figure 3 This is the initial screening result of cholesterol-lowering lactic acid bacteria.

[0013] Figure 4 This is the result of re-screening of cholesterol-lowering lactic acid bacteria.

[0014] Figure 5 It is a phylogenetic tree diagram.

[0015] Figure 6 This is a graph showing the effect of Lactococcus lactis subspecies inm3113 on the body weight of mice.

[0016] Figure 7 This is a diagram showing the effects of Lactococcus lactis subspecies inm3113 on mice. DETAILED DESCRIPTION

[0017] The present invention will be further described below in conjunction with specific embodiments:

[0018] Unless otherwise specified, the experimental methods used in the following embodiments are all conventional methods; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial channels.

[0019] Example 1, see attached Figure 1-7 , a strain of Lactococcus lactis subsp. lactis with cholesterol-lowering function, Lactococcus lactis subsp. lactis inm3113, was deposited in Guangdong Provincial Microbiological Culture Collection Center on July 17, 2024, with the deposit number: GDMCCNO: 64880; the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0020] A strain of Lactococcus lactis subspecies lactis having cholesterol-lowering function, having a 16S rDNA sequence as shown in SEQ ID NO: 1.

[0021] The invention discloses an application of Lactococcus lactis subspecies lactis with cholesterol-lowering function in the preparation of cholesterol-lowering products.

[0022] The invention discloses an application of Lactococcus lactis subspecies lactis with cholesterol-lowering function in the preparation of probiotic products.

[0023] Probiotic products include functional dairy products, functional beverages, fermentation agents, bacterial powders and bacteriocins. Figure 1-7 , a strain of Lactococcus lactis subsp. lactis with cholesterol-lowering function; 1 Materials and methods

[0024] 1.1 Materials and reagents

[0025] Dairy samples were obtained from Aba Tibetan and Qiang Autonomous Prefecture, Gannan Tibetan Autonomous Prefecture, and Inner Mongolia Autonomous Region; Lactobacillus acidophilus ATCC43121, Escherichia coli ATCC25922, and Salmonella typhimurium ATCC13311 were purchased from the American Type Culture Collection; Listeria monocytogenes CMCC54007 and Staphylococcus aureus CMCC26003 were purchased from the Chinese Medical Bacteria Collection Center; MRS agar medium and MRS broth medium were purchased from Qingdao Haibo Biotechnology Co., Ltd.; sodium chloride, disodium hydrogen phosphate, and sodium dihydrogen phosphate were purchased from Qingdao Haibo Biotechnology Co., Ltd. , glycerol (all of analytical grade), Sinopharm Chemical Reagent Co., Ltd.; skim milk powder, Fonterra Group Co., Ltd.; cholesterol, water-soluble cholesterol, Sigma-Aldrich (Shanghai) Trading Co., Ltd.; simvastatin, Sunflower Pharmaceutical Group (Hengshui) Defei Co., Ltd.; feed, Ruidi Biotechnology (Shenzhen) Co., Ltd.; total cholesterol (TC) test kit, triglyceride (TG) test kit, high-density lipoprotein (HDL-C) test kit, low-density lipoprotein (LDL-C) test kit, Nanjing Jiancheng Bioengineering Institute; the rest of the reagents were of analytical grade.

[0026] 1.2 Instruments and Equipment

[0027] 1260 InfinityⅡ analytical high performance liquid chromatography, 7890A gas chromatograph, HP-5 gas chromatography column, Agilent Technologies Co., Ltd.; MULTISKAN GO microplate reader: Thermo Fisher Scientific Co., Ltd.; 3K15 desktop refrigerated centrifuge: SIGMA Co., Ltd., Germany; LRH-250 biochemical incubator: Shanghai Yiheng Scientific Instrument Co., Ltd.

[0028] 1.3 Test methods

[0029] 1.3.1 Isolation and screening of lactic acid bacteria

[0030] After beating the dairy product sample evenly, take 25g of the sample and add it to 225g of sterile physiological saline, spread it on MRS solid culture medium after gradient dilution, and culture it at 37℃ for 48h, pick a single colony with lactic acid bacteria characteristics, and purify and culture it by plate streaking method (Screening of lactic acid bacteria in milk lumps in Yili area and study on their characteristics). The isolated strains with lactic acid bacteria characteristics were stored in a -80℃ refrigerator for testing.

[0031] 1.3.2 Preliminary screening of cholesterol-lowering Lactobacillus plantarum

[0032] MRS-cholesterol medium was prepared according to the method of Li Jingjing et al. (Screening and identification of lactic acid bacteria with potential to improve hyperlipidemia in fermented meat products). Activated Lactobacillus plantarum (1×10 9CFU / mL) was inoculated into MRS-cholesterol medium at a volume fraction of 5%, and after culturing at 37°C for 48 hours, the cholesterol content in the reaction system was determined by o-phthalaldehyde colorimetry (Screening of probiotic lactic acid bacteria for fermented vegetable-derived foods and evaluation of cholesterol-lowering ability), with an absorbance of 550nm. The cholesterol standard curve used in the experiment was A 胆固醇 =0.4513x+0.0567, R 2 =0.9984. The cholesterol degradation rate is calculated as shown in formula (1). X represents the absorbance, and R represents the slope of the standard curve;

[0033]

[0034] Where: C0 is the cholesterol content of the uninoculated culture medium, mg / mL; C1 is the cholesterol content of the inoculated culture medium, mg / mL.

[0035] 1.3.3 Rescreening of cholesterol-degrading lactic acid bacteria

[0036] The cholesterol-degrading Lactobacillus plantarum was screened by referring to the method of ZHENG et al., and the Lactobacillus acidophilus ATCC43121 strain with cholesterol-lowering effect was used as a positive control. The cholesterol degradation rate was calculated as shown in formula (2).

[0037]

[0038] Where: S0 is the cholesterol peak area of ​​the uninoculated culture medium; S1 is the cholesterol peak area of ​​the inoculated culture medium.

[0039] 1.3.4 Lactic acid bacteria antibiotic sensitivity test

[0040] Pour the bacterial suspension onto MRS solid culture medium and spread it evenly. Place a test paper containing antibiotics in the center of the culture medium. After culturing at 37°C for 24 hours, measure the diameter of the inhibition zone to evaluate the antibiotic sensitivity of the strain.

[0041] 1.3.5 Identification of bacterial species

[0042] DNA was extracted from the screened strains according to the instructions of the bacterial genomic DNA extraction kit, and PCR was performed using bacterial universal primers (27f: AGTTTGATCMTGGCTCAG, 1492r: GGTTACCTTGTTACGACTT). The PCR products were then sent to Shanghai Sangon Biotechnology Co., Ltd. for sequencing. The strain sequences were subjected to Blast analysis in NBCI, and a phylogenetic tree was constructed using MEGA11 software.

[0043] 1.3.6 Evaluation of antibacterial properties of lactic acid bacteria metabolites

[0044] After the lactic acid bacteria were fully activated, they were inoculated into MRS liquid culture medium and cultured anaerobically at 37°C for 24 hours. The culture medium was centrifuged at 12000 r / min for 5 minutes, and the supernatant was taken to evaluate the antibacterial properties of lactic acid bacteria metabolites against Escherichia coli ATCC25922, Salmonella typhimurium ATCC13311, Listeria monocytogenes CMCC54007, and Staphylococcus aureus CMCC26003 using the Oxford cup method.

[0045] 1.3.7 Preparation of freeze-dried powder

[0046] Weigh 12g skim milk powder, 5g glycerol, and 83g sterile water, mix well, and sterilize under high pressure (121°C, 15min) to obtain a lyophilized protective agent. Inoculate the activated strain into MRS liquid culture medium, culture anaerobically at 37°C for 24h, then centrifuge to obtain the precipitate, wash with sterile saline, add a lyophilized protective agent, pre-freeze at -80°C, and freeze-dry for 24h. Use the pour plate method to determine the number of viable bacteria, and then store the lyophilized powder at -20°C.

[0047] 1.3.8 Evaluation of the effects of lactic acid bacteria on mice

[0048] Thirty-six C57BL / 6 male mice aged 4 to 6 weeks and weighing 17 to 19 g (produced by Shanghai Shengchang Biotechnology Co., Ltd., Laboratory Animal Use Permit: SYXK (Shanghai) 2014-0018) were randomly divided into 6 groups after acclimatization for 1 week. The mice were fed according to Table 1, and their body weights were weighed every week. After 8 weeks, the livers of the mice were taken and the fat was weighed. The eyeballs were removed to collect blood and separate the serum, and TC, TG, HDL-C and LDL-C were detected according to the instructions of the kit.

[0049] Table 1 Experimental grouping table

[0050] Grouping Feeding Oral gavage Blank group Basic feed + water 0.9% saline Model Group High fat diet + water 0.9% saline Positive control group High fat diet + water Simvastatin (2 mg / kg) Inm3113 Group High fat diet + water <![CDATA[Inm3113 bacterial suspension (1×10 9 CFU / mL)]]>

[0051] 1.4 Data Processing

[0052] Data are expressed as mean ± standard deviation. Graphpad Prism 8.0 software was used for statistical analysis and image drawing.

[0053] 2 Experiments and Results

[0054] 2.1 Preliminary screening of cholesterol-lowering lactic acid bacteria

[0055] Twenty-two strains with potential cholesterol degradation ability were screened from natural fermented milk samples. The test results are as follows: Figure 3The cholesterol degradation rate of the strains was 7.21% to 59.44%, among which the strain with the highest degradation rate was inm3113, which reached 59.44%, while inm2401, inm1203, and inm0501 strains also showed good cholesterol degradation ability, with degradation rates of 50.26%, 50.05%, and 47.03%, respectively. Therefore, inm3113, inm2401, inm1203, and inm0501 strains were selected for subsequent experiments.

[0056] 2.2 Cholesterol-lowering lactic acid bacteria rescreening

[0057] To further verify the cholesterol degradation ability of the strains, the cholesterol degradation potential of inm2401, inm1203, and inm0501 was evaluated again by gas chromatography, with Lactobacillus acidophilus ATCC43121 as a positive control. Figure 4 As shown, the strain with the highest cholesterol degradation rate was inm3113, with a degradation rate of 30.03%, which was 129.59% higher than that of the positive control strain Lactobacillus acidophilus ATCC43121. Therefore, Lactococcus lactis subsp. lactis inm3113 was selected for subsequent experiments.

[0058] 2.3 Antibiotic sensitivity of inm3113 strain

[0059] The results of the sensitivity test of the inm3113 strain to common antibiotics used in the experiment are shown in Table 2. The strain is most sensitive to tetracycline, with the diameter of the inhibition zone reaching (34.04±0.24) mm. It also has good sensitivity to cefazolin, gentamicin and ampicillin, indicating that the inm3113 strain has a certain degree of safety.

[0060] Table 2 Antibiotic sensitivity of inm3113

[0061] Drug Name Drug content / (μg / tablet) Diameter of inhibition zone / mm Sensitivity penicillin 10 5.59±0.36 R Cefazolin 30 25.40±0.92 S tetracycline 30 34.04±0.24 S Gentamycin 10 16.84±0.29 S Erythromycin 15 21.65±0.57 I Ciprofloxacin 5 11.65±0.46 R Ampicillin 10 26.69±0.34 S

[0062] Note: S stands for sensitive; I stands for normal; R stands for insensitive.

[0063] 2.4 Strain identification

[0064] The strain sequence was subjected to Blast analysis in NBCI, and the phylogenetic tree was constructed using MEGA11 software. The results are as follows: Figure 5 It can be inferred that the inm3113 strain isolated from fermented milk belongs to Lactococcus lactis subsp. lactis.

[0065] 2.5 Antibacterial properties of inm3113 strain metabolites

[0066] As shown in Table 3, the metabolites of the Inm3113 strain had a certain inhibitory effect on the four intestinal pathogens. Among them, the strain metabolites had the strongest inhibitory effect on the Gram-positive bacteria Escherichia coli O157∶H7 ATCC25922, with an inhibition zone diameter of 17.80±0.42mm, followed by the Gram-negative bacteria Listeria monocytogenes CMCC54007, with an inhibition zone diameter of 10.56±0.84mm.

[0067] Table 3 Antibacterial properties of inm3113

[0068]

[0069] Effects of 2.6inm3113 strain on hypercholesterolemia mice

[0070] 2.6.1 Effect of inm3113 strain on mouse body weight

[0071] like Figure 6 As shown, during the 56-day dosing cycle, the weight of mice in the model group increased significantly faster than that of the other groups. By day 56, the weight of mice in the model group had increased by 97.70%, while the weight of mice in the blank group, positive control group, and inm3113 group had increased by 58.94%, 58.02%, and 58.06%, respectively, compared with the initial weight. This indicates that inm3113 can effectively reduce the rate of weight gain in mice fed a high-fat diet, and has an effect close to that of the positive control simvastatin.

[0072] 2.6.2 Effects of inm3113 strain on mouse serum parameters

[0073] like Figure 7 As shown in the figure, compared with the blank group mice fed with ordinary feed, the model group mice fed with high-fat feed had significantly increased serum cholesterol, serum triglyceride, and low-density lipoprotein concentrations after 56 days of feeding, reaching 4.365±0.488 (mmmol / L), 1.613±0.212 (mmmol / L), and 1.154±0.131 (mmmol / L), respectively. When fed with high-fat feed, oral administration of inm3113 bacterial suspension can slow down the increase in serum cholesterol, serum triglyceride, and low-density lipoprotein concentrations. The serum cholesterol, serum triglyceride, and low-density lipoprotein concentrations of inm3113 group mice were 31.66%, 62.25%, and 45.76% lower than those of the model group, respectively. Figure 7 A, B, D), while the above indicators of the positive control group were 34.92%, 66.39%, and 45.11% lower than those of the blank group, respectively. This result showed that the inm3113 strain improved the symptoms of hypercholesterolemia mice and showed an effect close to that of the positive control simvastatin.

[0074] 3 Conclusion

[0075] The Lactococcus lactis subspecies inm3113 screened out in this study had a cholesterol degradation rate of 30.03% in the gas chromatography test, which was 129.50% higher than that of the positive control strain Lactobacillus acidophilus ATCC43121. In the mouse experiment, it could delay the rate of weight gain of mice fed with a high-fat diet and regulate the concentrations of serum cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein. In the antibacterial experiment, the metabolites of this strain had a certain inhibitory effect on Staphylococcus aureus CMCC26003, Listeria monocytogenes CMCC54007, Escherichia coli O157:H7ATCC25922 and Salmonella typhimurium ATCC13311, and showed good sensitivity to four common antibiotics (ampicillin, cefazolin, gentamicin and tetracycline). Therefore, the Lactococcus lactis subspecies inm3113 screened in this study has good cholesterol-lowering ability and probiotic properties, good safety, and certain industrial value.

[0076] Lactococcus lactis subsp. lactis inm3113 was identified by gene, and its gene sequence is as follows:

[0077] ACTTAGGAGCGCCCTCCTTGCGGTTAGGCAACCTACTTCGGGTACTCCCAACTCCCGTG

[0078] GTGTGACGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCGTGCTGATCCGCGATT

[0079] ACTAGCGATTCCGACTTCATGTAGGCGAGTTGCAGCCTACAATCCGAACTGAGAATGGTTTTTA

[0080] AGAGATTAGCTAAACATCACTGTCTCGCGACTCGTTGTACCATCCATTGTAGCACGTGTGTAG

[0081] CCCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTTCCTCCGGTTTATCACCGGC

[0082] AGTCTCGTTAGAGTGCCCAACTTAATGATGGCAACTAACAATAGGGGTTGCGCTCGTTGCGGG

[0083] ACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTATCCCGTGTCC

[0084] CGAAGGAACTTCCTATCTCTAGGAATAGCACGAGTATGTCAAGACCTGGTAAGGTTCTTCGCG

[0085] TTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTT

[0086] CAACCTTGCGGTCGTACTCCCCAGGCGGAGTGCTTATTGCGTTAGCTGCGATACAGAGAACTT

[0087] ATAGCTCCCTACATCTAGCACTCATCGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTT

[0088] TGCTCCCCACGCTTTCGAGCCTCAGTGTCAGTTACAGGCCAGAGAGCCGCTTTCGCCACCGGT

[0089] GTTCCTCCATATATCTACGCATTTCACCGCTACACATGGAATTCCACTCTCCTCTCCTGCACT

[0090] CAAGTCTACCAGTTTCCAATGCATACAATGGTTGAGCCACTGCCTTTTACACCAGACTTAATA

[0091] AACCACCTGCGCTCGCTTTACGCCCAATAAATCCGGACAACGCTCGGGACCTACGTATTACCG

[0092] CGGCTGCTGGCACGTAGTTAGCCGTCCCTTTCTGGGTAGTTACCGTCACTTGATGAGCTTTCC

[0093] ACTCTCACCAACGTTCTTCTCTACCAACAGAGTTTTACGATCCGAAAACCTTCTTCACTCACG

[0094] CGGCGTTGCTCGGTCAGACTTTCGTCCATTGCCGAAGATTCCCTACTGCTGCCTCCCGTAGGA

[0095] GTTTGGGCCGTGTCTCAGTCCCAATGTGGCCGATCACCCTCTCAGGTCGGCTATGTATCATCG

[0096] CCTTGGTGAGCCTTTACCTCACCAACTAGCTAATACAACGCGGGATCATCTTTGAGTGATGCA

[0097] ATTGCATCTTTCAAACTTAAAACTTGTGTTTAAAGTTTTTATGCGGTATTAGCATTCGTTTCC

[0098] AAATGTTGTCCCCCGCTCAAAGGCAGATTCCCCACGCGTTACTCACCCGTTCGCTGCTCATCC

[0099] AGTCGGTACAAGTACCAACCTTTCAGCGCTCAACTGCA

[0100] The above-mentioned embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims.

Claims

1. A strain of Lactococcus lactis subsp. lactis having cholesterol-lowering function, characterized in that: Lactococcus lactis subsp. lactis inm3113 was deposited in Guangdong Microbiological Culture Collection Center on July 17, 2024, with the deposit number: GDMCC NO:64880; Storage address: 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou.

2. The strain of Lactococcus lactis subsp. lactis having cholesterol-lowering function according to claim 1, characterized in that: The gene has a 16S rDNA sequence as shown in SEQ ID NO:

1.

3. Use of the Lactococcus lactis subspecies lactis with cholesterol-lowering function according to claim 1 in the preparation of cholesterol-lowering products.

4. Use of the Lactococcus lactis subspecies lactis with cholesterol-lowering function according to claim 1 in the preparation of probiotic products.

5. The use of Lactococcus lactis subsp. lactis with cholesterol-lowering function in the preparation of probiotic products according to claim 4, characterized in that: Probiotic products include functional dairy products, functional beverages, fermentation cultures, bacterial powders and bacteriocins.

Citation Information

Patent Citations

  • Lactococcus lactis capable of lowering cholesterol and producing extracellular polysaccharide

    CN102604851A

  • Production method of sour milk with high vitamin B2 for lowering cholesterol

    CN1596678A